Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety

Inclusion Criteria:

• Subjects with a diagnosis of eczema, fulfil the 3 follow items: 1) Erythema,papilla/water blister, Lichenification, skin damage with infiltration, 2) unknownreason, recurrent attacks; 3) itching in diseased skin

• Subjects must have body surface area (BSA) disease involvement of less than or equalto 10% as assessed by palm method

• Subject must present with moderate and above eczema as defined by a score greater thanor equal to 3 using the investigators global assessment (IGA) of eczema severity.

Exclusion Criteria:

• The subject presents with any systemic disorder or active skin disease (e.g.psoriasis) that would in any way confound interpretation of the study results orsubjects who present with scars, moles, tattoos, body piercings, sunburn in the testarea which could interfere with the assessment of lesions at screening.

• The subject has eczema restricted to the face, the feet or the hands only.

• The subject is indicated any anti-infectives drug for a current complication of overtbacterial, fungal and viral infection

• History of recent (<1 month) active or presence of current superficial skin infectionsof viral aetiology such as herpes simplex, or varicella.

• The subject has been exposed to below therapy within the set timeframe: Topical agentsadministered in the diseased skin, including emollient - 1 week; Systemicadministration of anti-histamine agents - 2 week; Systemic administration ofcorticosteroid -4 week; Systemic administration of immunosuppressive drugs - 4 week;UV therapy -4 week

• Foreseeable intensive ultraviolet (UV) exposure during the study (solar orartificial). Subjects must not be exposed to intense direct sunlight for long periods,and must not use skin tanning devices (e.g. sunbed) for the duration of the study.

• History of clinically significant cardiovascular, pulmonary, gastrointestinal, liver,neurological, renal or haematological abnormalities.

• History of allergy to components of test medications to be used in the study.

• History of anaphylaxis (a sudden, potentially life-threatening systemic allergicreaction) to food, medications, insect venom, or latex.